New hope for Alzheimer's: Information evening on therapy with Lecanemab

New hope for Alzheimer's: Information evening on therapy with Lecanemab

In recent weeks, the topic of Alzheimer's dementia has stirred up a lot of dust due to the introduction of a new drug, Lecanemab, in Germany. Next Monday, September 22nd at 7 p.m., the St. Augustinus Group invites you to an information event at the Memory Center, Steinhausstraße 40 in Neuss. The focus is on the new drug therapy options that are available for early Alzheimer's dementia. LocalClick reports that Dr. Anna Artmann, doctor at the Memory Center, will lead the event.

What makes this medication so special? Lecanemab is an antibody that targets amyloid plaques in the brain and activates the immune system to break down these harmful deposits. It was approved in Germany on September 1, 2025, after the European Commission gave its approval in April 2025. The drug is also known as Leqembi and has been on the market in the USA and Japan since 2023. The pharmacies look around indicates that it is suitable for a specific group of patients who must meet strict criteria.

Treatable patients and therapeutic approach

How many patients in Germany could benefit from this treatment? It is estimated that between 12,000 and 200,000 Alzheimer's patients are potentially eligible, with the therapy primarily aimed at people with mild cognitive impairment in the early stages of the disease. This is estimated to affect around 73,000 of the 460,000 patients with mild dementia in Germany. Report from BR shows that extensive examinations are necessary to identify suitable patients.

Lecanemab treatment requires intensive follow-up. The infusion must be administered every 14 days and during this time patients should remain under medical supervision. MRI examinations are required at least once a year in order to detect any side effects such as brain swelling or bleeding in good time.

Costs and reimbursements

The costs for the therapy are not without their costs: they are estimated to be around 30,000 euros per year per patient in Europe. While the treatment and test costs are initially covered by the health insurance companies, the Federal Joint Committee decides on long-term cost coverage after a comprehensive benefit assessment has been carried out. The Dutch market, where the treatment is also approved, may soon follow as other countries also show interest in the availability of lecanemab.

Anyone interested should not miss the opportunity to take part in the information event. Registration is free, but we recommend that you register in advance by phone on 02131 529 65333 or by email at empfang-amz@ak-neuss.de to secure a place.